<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321240</url>
  </required_header>
  <id_info>
    <org_study_id>6647</org_study_id>
    <nct_id>NCT03321240</nct_id>
  </id_info>
  <brief_title>Study of Predictive Biomarkers for Rational Management of Drug-resistant Epilepsy Associated With Focal Cortical Dysplasia</brief_title>
  <acronym>SPREAD</acronym>
  <official_title>Study of Predictive Biomarkers for Rational Management of Drug-resistant Epilepsy Associated With Focal Cortical Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Focal Cortical Dysplasias (FCDs) are neurodevelopmental disorders that represent a major
      cause of early onset drug-resistant epilepsies with cognitive and behavioral impairments,
      carrying a lifelong perspective of disability and reduced quality of life. Despite a major
      medical and socio-economic burden, rationale therapeutic strategies are still under debate.
      Surgical removal of the epileptogenic brain area (Epileptogenic Zone) is the most successful
      treatment, yet it fails to control FCD-associated seizures in as much as 40% of cases.
      Precise definition and complete resection of the Epileptogenic Zone are the main determinants
      of outcome. In current practice of French centers, up to 80% FCD-patients require an
      intracranial EEG (icEEG) recording to accurately define the epileptogenic zone. However, the
      indications for icEEG in MRI-visible FCD remain empirical and are essentially based on expert
      opinion.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of seizure-free patients (Engel class I) at 12-months follow-up after resective surgery.</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of each of six seizure-onset pattern types within each of three histologically defined subgroups (FCD type I, FCD type II, non-pathologic findings).</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of epilepsy before surgery in patients with focal and network epileptogenic zone (defined by EI)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topographic distribution of structures that disclose high Epileptogenicity Index values (EI&gt;0.4), of structures with maximal interictal HFO rates and of structures showing interictal/preictal functional connectivity alterations</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Refractory Epilepsy</condition>
  <condition>Focal Epilepsy</condition>
  <condition>Focal Cortical Dysplasia</condition>
  <arm_group>
    <arm_group_label>The SEEG group</arm_group_label>
    <description>Group with the SEEG analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The direct surgery group</arm_group_label>
    <description>Group with a direct surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>visual and quantitative SEEG signal analysis</intervention_name>
    <description>signal SEEG analysis</description>
    <arm_group_label>The SEEG group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resective epilepsy surgery procedure</intervention_name>
    <description>Surgical removal of the epileptogenic brain area</description>
    <arm_group_label>The SEEG group</arm_group_label>
    <arm_group_label>The direct surgery group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample and resected brain tissue specimen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult or pediatric (Age more than 2 years old) patients attending tertiary epilepsy center
        for presurgical evaluation of refractory focal epilepsy compatible with FCD
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult or pediatric patient suffering from drug-resistant focal epilepsy;

          -  Age more than 2 years old;

          -  Brain MRI suggestive of FCD or normal;

          -  Standardized presurgical evaluation available including medical history, scalp
             video-EEG, 3T MRI, FDG-PET, Neuropsychological tests;

          -  Inpatient in one of the participating centers for recording seizure during long term
             scalp video-EEG and / or SEEG-monitoring;

          -  Resective surgery with a minimal post-operative follow-up of 12 months;

          -  Histopathologic evidence for FCD or non-pathologic findings (normal histology or mMCD
             type II).

          -  Patient, parents or legally representative who have given written informed consent to
             allow the study data collection procedures.

        Exclusion Criteria:

          -  Brain MRI suggestive of another type of lesion;

          -  Difficulty to read or understand French, or inability to understand the information;

          -  Pregnant or breastfeeding woman;

          -  Subject under judicial protection.

          -  Other lesion discovered on histological examination;

          -  FCD type 3, dual pathology, ambiguous or unavailable neuropathological findings

          -  Lack of longitudinal pre- and post-surgical follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edouard HIRSCH</last_name>
    <phone>+33 3 88 12 85 62</phone>
    <email>edouard.hirsch@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia SCHOLLY</last_name>
    <phone>+33 3 88 12 85 78</phone>
    <email>julia.scholly@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Michallon Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe KAHANE</last_name>
      <phone>+33 4 76 76 54 48</phone>
      <email>philippe.kahane@univ-grenoble-alpes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William SZURHAJ</last_name>
      <phone>+33 3 20 44 63 73</phone>
      <email>william.szurhaj@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain RHEIMS</last_name>
      <phone>+33 4 72 3570 44</phone>
      <email>sylvain.rheims@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Timone Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice BARTOLOMEI</last_name>
      <phone>+33 4 91 38 49 90</phone>
      <email>fabrice.bartolomei@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louis MAILLARD</last_name>
      <phone>+33 3 83 85 23 79</phone>
      <email>l.maillard@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GH Pitie-Salpêtrière-Charles Foix</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent NAVARRO</last_name>
      <phone>+33 1 42 16 18 13</phone>
      <email>vincent.navarro@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Necker-Enfants Malades Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>KAMINSKA Anna</last_name>
      <phone>+33 1 44 45 18 50</phone>
      <email>anna.kaminska@nck.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rothschild Foundation</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathilde CHIPAUX, MD</last_name>
      <phone>+33 1 48 03 69 43</phone>
      <email>mchipaux@for.paris</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anca NICA</last_name>
      <phone>+33 2 99 28 43 21</phone>
      <email>Anca.NICA@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edouard HIRSCH</last_name>
      <phone>+33 3 88 12 85 62</phone>
      <email>edouard.hirsch@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julia SCHOLLY</last_name>
      <phone>+33 3 88 12 85 78</phone>
      <email>julia.scholly@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Charles BEHR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edouard HIRSCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia SCHOLLY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc VALTON</last_name>
      <phone>+33 5 61 77 94 88</phone>
      <email>valton.l@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>focal cortical dysplasia</keyword>
  <keyword>Pronostic</keyword>
  <keyword>Epilepsy surgery</keyword>
  <keyword>Epiletogenicity index</keyword>
  <keyword>SEEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
    <mesh_term>Malformations of Cortical Development</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

